Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Equillium Inc (EQ)
Equillium Inc (EQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
3 Brilliant Biotech Stocks to Buy for Your Portfolio

The biotech industry is flourishing on the backs of positive clinical trials and new developments. Thus, it could be beneficial to add fundamentally robust biotech stocks BioMarin Pharmaceutical (BMRN),...

BMRN : 89.25 (-1.24%)
EQ : 0.7260 (+0.14%)
ORGO : 3.39 (+27.92%)
Top 3 Biotech Stocks to Watch and Buy for Healthy Profits

With innovative approaches and cutting-edge technologies, biotech has ushered in a new era of possibilities in the medical field. Hence, investing in three fundamentally sound biotech stocks, Equillium,...

EQ : 0.7260 (+0.14%)
EXEL : 22.39 (+0.90%)
THTX : 2.18 (+1.40%)
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders...

EQ : 0.7260 (+0.14%)
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders...

EQ : 0.7260 (+0.14%)
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced...

EQ : 0.7260 (+0.14%)
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an oral presentation...

EQ : 0.7260 (+0.14%)
Equillium to Present at the SVB Securities Annual Global Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced...

EQ : 0.7260 (+0.14%)
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was...

EQ : 0.7260 (+0.14%)
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement

Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement.

EQ : 0.7260 (+0.14%)
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited,...

EQ : 0.7260 (+0.14%)

Barchart Exclusives

Down 13% from 52-Week Highs, Is Amazon Stock a Buy Now?
Amazon stock is down more than 13% from the 52-week highs that it hit earlier this month. Why is AMZN stock dropping, and should you buy the dip? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar